Effects of Recombinant Human Erythropoietin (rHuEPO) on Tumor Control in Patients with Cancer-Induced Anemia

Publisher： Karger

E-ISSN： 2296-5262|28|4|216-221

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.28, Iss.4, 2005-10, pp. : 216-221

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prevention of Anemia in Patients with Solid Tumors Receiving Platinum-Based Chemotherapy by Recombinant Human Erythropoietin (rHuEpo): A Prospective, Open Label, Randomized Trial by the Hellenic Cooperative Oncology Group

By  

Oncology, Vol. 64, Iss. 2, 2003-02 ,pp. : 102-110

Karger

Access to resources Recommend Favorite

Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes

By  

Acta Haematologica, Vol. 120, Iss. 2, 2008-10 ,pp. : 104-107

Karger

Access to resources Recommend Favorite

Recombinant Human Erythropoietin in the Treatment of Chronic Anemia of Cancer

By  

Acta Haematologica, Vol. 100, Iss. 2, 1998-10 ,pp. : 115-115

Karger

Access to resources Recommend Favorite

rHuEPO Dose Inversely Correlated with the Number of Circulating CD34+ Cells in Maintenance Hemodialysis Patients

By  

Nephron Clin Pract, Vol. 108, Iss. 1, 2007-12 ,pp. : c41-c46

Karger

Access to resources Recommend Favorite

The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin

By Devine E. B.   Cross J. T.   Kowdley K. V.   Sullivan S. D.  

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1463-1472

Informa Healthcare

Access to resources Recommend Favorite